Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Lipocine (LPCN) Gains from Sales and Divestitures (2019 - 2025)

Lipocine's Gains from Sales and Divestitures history spans 3 years, with the latest figure at $3625.0 for Q3 2025.

For Q3 2025, Gains from Sales and Divestitures changed N/A year-over-year to $3625.0; the TTM value through Sep 2025 reached $3625.0, changed N/A, while the annual FY2020 figure was $628807.0, 154.06% up from the prior year.
Gains from Sales and Divestitures reached $3625.0 in Q3 2025 per LPCN's latest filing, up from $2416.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $3625.0 in Q3 2025 to a low of $2416.0 in Q1 2025.